Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma

SIMPLE SUMMARY: Approximately one in seven patients with classical Hodgkin lymphoma have refractory disease or relapse after standard front line chemotherapy. Prognostic biomarkers could help determine candidates for more effective treatment. The latest advances in research techniques have contribut...

Descripción completa

Detalles Bibliográficos
Autores principales: Martynchyk, Arina, Chowdhury, Rakin, Hawkes, Eliza A., Keane, Colm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649036/
https://www.ncbi.nlm.nih.gov/pubmed/37958391
http://dx.doi.org/10.3390/cancers15215217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649036/
https://www.ncbi.nlm.nih.gov/pubmed/37958391
http://dx.doi.org/10.3390/cancers15215217

Ejemplares similares